Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VB10.NEO + Atezolizumab in Advanced Tumors
NCT05018273Phase 1Completed
- Sponsor
- Nykode Therapeutics
- Start
- Dec 2021
- Primary completion
- Oct 2024
- Modality
- Prophylactic Vaccines, Therapeutic Vaccines, DNA Vaccines
- Countries
- 3
01
Overview
Phase 1, open-label trial of VB10.NEO in melanoma, non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC) and 7 more (3 arms), sponsored by Nykode Therapeutics. Primary endpoints: Incidence and severity of adverse events up to 27 months, Changes from baseline in vital signs up to 27 months and 1 more. Started Dec 2021; status: completed.
02
Drugs
VB10.NEO
03
Conditions
melanomanon-small cell lung cancer (NSCLC)renal cell carcinoma (RCC)urothelial carcinoma (UC)head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT05018273.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05018273.